Incyte (INCY) PT Lowered to $78 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Incyte Reports 2018 Third Quarter and Nine Month Financial Results and Provides Updates on Key Clinical Programs
October 30, 2018 7:00 AM EDTTotal product-related revenues of $430 million for the three months and $1.2 billion for the nine months ended September 30, 2018; Jakafi® (ruxolitinib) revenues of $348 million in 3Q 2018 and $1.0 billion YTD 2018 sNDA for ruxolitinib for the treatment of patients with steroid-refractory acute graft versus host disease (GVHD) accepted by the FDA for Priority Review Compelling data from pemigatinib (FGFR) and capmatinib (MET, with Novartis) programs presented at ESMO; NDAs seeking approval of both compounds expected next year Positive proof-of-concept data for... More
